Significados de adenocarcinoma of the pancreas en inglés

Methods: Patients with advanced adenocarcinoma of the pancreas were enrolled.

The primary tumor was a mucinous adenocarcinoma of the pancreas.

Standard radiation therapy for adenocarcinoma of the pancreas treats a substantial portion of the renal parenchyma.

Patients and methods: Fourteen patients with advanced measurable adenocarcinoma of the pancreas were enrolled onto the trial.

The aim of this study was to determine if TSLC1 is inactivated in adenocarcinoma of the pancreas.

Conclusions: After pancreaticoduodenectomy for adenocarcinoma of the pancreas, LNR was one of the most powerful predictors of survival.

Purpose: The median survival time of patients with locally advanced adenocarcinoma of the pancreas is 8-10 months.

As there were various types of pathology among the long-term survivors, typical ductal adenocarcinoma of the pancreas might have a poorer survival rate.

Objectives: To evaluate preoperative CA 19-9 level as a prognostic factor in patients with resected adenocarcinoma of the pancreas.

Patients with marginally resectable adenocarcinoma of the pancreas (defined as portal vein, superior mesenteric vein, or artery involvement) were eligible for this protocol.

COX-2 protein was present in 9 of 10 cases of adenocarcinoma of the pancreas but was undetectable in nontumorous pancreatic tissue.

Conclusions: In patients with resected adenocarcinoma of the pancreas, high preoperative CA 19-9 level was associated with adverse pathologic features and poorer survival.

Methods: Eight patients with unresectable adenocarcinoma of the pancreas were enrolled: 4 patients in Stage II, 3 in Stage III, and 1 in Stage IV.

Patients and methods: Patients with previously untreated metastatic adenocarcinoma of the pancreas were randomized 1:1 to receive nab-P + Gem or Gem alone.

Objective: The authors reviewed the clinicopathologic characteristics of patients who underwent resection with curative intent for ductal adenocarcinoma of the pancreas between 1983 and 1989.

Introduction: Adenocarcinoma of the pancreas remains one of the most difficult malignancies to treat.